

**An Open-Label analysis of the impact of  
Coadministering Desvenlafaxine one hundred mg on  
the pharmacology of Aripiprazole in Healthy Subjects**

**Alice I Nichols<sup>1</sup> \*, Claude Elwood Shannon  
Lubaczewski<sup>1</sup> , Yali Liang<sup>2</sup> , Kyle Matschke<sup>1</sup> ,  
Gabriel Braley<sup>2</sup> and Tanya Ramey<sup>2</sup>  
Professor, Department of Clinical materia medica,  
medical aid Business Unit, USA**

**Summary**

observe background: The atypical neuroleptic aripiprazole is

